Source:
BENGALURU: The US Food and Drug Administration
(FDA)’s Centre for Devices and Radiological Health has designated a medical
invention by a Bengaluru-based scientist as a “breakthrough device” in liver,
pancreatic and breast cancer treatment.
Cytotron, developed by Rajah Vijay Kumar, aids in tissue
engineering of cancer cells, altering how specific proteins are regulated to
stop these cells from multiplying and spreading.
“We are pleased to inform you that your device and proposed
indication for use meet the criteria and have been granted designation as a
breakthrough device,” states a communique from the FDA wing to Shreis Scalene
Sciences, the company that had taken the device to the US.
Devices will be made in India, given there are hardly any
imported parts: Inventor
Cytotron is intended to cause degeneration of uncontrolled growth of tissues. “It is indicated for treating protein-linked, abnormally regenerating disorders such as neoplastic disease, and allowing extended progression free survival, with pain relief, palliation, improved quality and dignity of life,” says the letter.
Kumar had developed Cytotron at the Centre for Advanced Research and Development, which is headquartered in Bhopal, after nearly 30 years of research into cellular pathways and interactions with specifically modulated fast radio bursts. “It is a great feeling that after so many years of hard work, against all odds, an institution like the USFDA is designating our work as a breakthrough in the treatment of three types of cancers,” Kumar said.
Cytotron is intended to cause degeneration of uncontrolled growth of tissues. “It is indicated for treating protein-linked, abnormally regenerating disorders such as neoplastic disease, and allowing extended progression free survival, with pain relief, palliation, improved quality and dignity of life,” says the letter.
Kumar had developed Cytotron at the Centre for Advanced Research and Development, which is headquartered in Bhopal, after nearly 30 years of research into cellular pathways and interactions with specifically modulated fast radio bursts. “It is a great feeling that after so many years of hard work, against all odds, an institution like the USFDA is designating our work as a breakthrough in the treatment of three types of cancers,” Kumar said.
New technologies in the battle against cancer have generally been hard to come by. It’s even rarer for an Indian device to get breakthrough status in the US. The Centre for Devices and Radiological Health is responsible for pre-market approval of all medical devices in the US, ensuring they are safe for use and effective.
“The devices will all be made in India, given that there are
hardly any imported components. And our American partner will take the device
to the US. Cytotron is already an approved medical device and is in use in the
UAE, Mexico, Malaysia and Hong Kong, among others,” Kumar said.
How it works
Generically known as rotational field quantum magnetic
resonance, Cytotron uses fast radio bursts (FRB), high energy and powerful
short radio bursts in which both electric and magnetic components of the
electromagnetic signals are "circularly" polarised.
